Almstead Neil Gregory Sells PTC Therapeutics Shares
PTC Therapeutics' Chief Technical Officer sold shares worth $693,151 under a planned sale.
Key Points
- On June 26, 2026, Almstead Neil Gregory, Chief Technical Ops Officer at PTC Therapeutics, sold 8,130 shares, valued at $693,151, as part of a planned transaction.
- PTC Therapeutics, trading on NasdaqGS, has a market cap of about $7 billion, with a forward P/E of 30.3 and a 52-week high of $87.50.
- BlackRock, Inc. increased its holdings in PTC Therapeutics by 169,652 shares, while Janus Henderson Group PLC boosted its stake by 48.3%.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, Almstead Neil Gregory, the Chief Technical Ops Officer at PTC Therapeutics, Inc. (NasdaqGS: PTCT), sold 8,130 shares of the company. The shares were sold at an average price of $85.26, totaling approximately $693,151. This transaction was part of a planned sale.
Insider Buying and Selling at PTC Therapeutics, Inc.
Neil Gregory's recent sale was not his only transaction. On the same day, he also executed a planned sale of 8,130 shares at the same price. Previously, on June 25, 2026, he sold 20,960 shares at an average price of $85.97, while also buying 20,960 shares at an average price of $38.11.
PTC Therapeutics, Inc. Stock Up 17.3%
Shares of PTC Therapeutics traded near $81.57 on Wednesday. The company has a market capitalization of approximately $7 billion and a forward P/E ratio of 30.3, reflecting its valuation relative to future earnings. The stock has seen a 52-week range between $43.18 and $87.50. PTC's 50-day moving average stands at $72.22, and its 200-day moving average is $70.94. The company's current ratio is 2.44, indicating its ability to cover short-term liabilities.
$PTCT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 9, 2026, Citigroup assumed coverage on PTC Therapeutics with a 'buy' rating and set a price target of $108. Previously, Jefferies upgraded the stock to 'buy' on May 27, 2026, with a target of $85. TD Cowen also upgraded the stock to 'buy' on May 8, 2026, setting a target of $90. The consensus among analysts is a 'buy', with a mean target price of $93.93 from 14 opinions.
Other Institutional Activity in PTC Therapeutics
BlackRock, Inc. grew its holdings in PTC Therapeutics by 169,652 shares, ending with 12,948,717 shares valued at about $882.2 million. Janus Henderson Group PLC significantly boosted its stake by 48.3%, adding 2,342,101 shares to reach a total of 7,193,433 shares worth approximately $490 million. Vanguard Portfolio Management LLC opened a new position with 4,804,594 shares valued at $327.3 million. Meanwhile, State Street Corp increased its holdings by 140,393 shares, resulting in a total of 4,346,519 shares valued at $296.1 million.
About PTC Therapeutics
PTC Therapeutics, Inc., based in Warren, New Jersey, is a biopharmaceutical company specializing in the discovery and development of medicines for rare disorders. The company markets several treatments, including Translarna and Emflaza for Duchenne muscular dystrophy, and Upstaza for AADC deficiency. PTC Therapeutics is also involved in developing therapies for conditions like Huntington's disease and Friedreich's ataxia. The company collaborates with major pharmaceutical firms and distributes its products globally.
Bottom Line
Almstead Neil Gregory's recent insider sale at PTC Therapeutics highlights ongoing executive activity within the company. As investors track these movements, it's important to remember that the disclosed transactions may be part of planned sales. PTC Therapeutics continues to be a focus in the biotech sector, with analysts maintaining a positive outlook on its stock, underpinned by the company's strategic partnerships and innovative pipeline.
Get PTC Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PTCT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.